At age 18, Chris didn't worry too much about his health. So, after experiencing occasional double vision—and visiting a neural ophthalmologist who couldn't find the cause—he didn't dwell on it. The problem eventually went away, and he left home to start college at Colgate University.
During his freshman year, Chris had occasional symptoms like trouble urinating and a feeling of electric pulses running up the back of his neck. He figured they were related to stress or an injury suffered while playing rugby. Instead, they were signs that something was wrong.
The following August, Chris was on vacation on the Massachusetts island of Nantucket. Upon waking up one morning, he couldn't walk straight or urinate. His eyes ached as well.
A local hospital performed a CT scan that detected an abnormality near the base of his skull. Since the hospital was not equipped to handle a case like this, he was airlifted to Mass General.
Chris' tumor had developed near his skull base. This type of chordoma rarely spreads to other organs. And though it can come back, it usually does so in the same location. For these reasons, people with a skull base chordoma tend to have a "relatively favorable prognosis," according to Dr. MacDonald.
The first step in chordoma treatment is surgically resecting, or removing, as much of the tumor as possible. Due to their sensitive location, skull base chordomas cannot be completely removed. At Mass General Cancer Center, a team of skull base experts, including neurosurgeons and plastic surgeons, operated on Chris. The procedure took upwards of 14 hours.
About a week later, Chris and his family met Dr. Liebsch for the first time to discuss his upcoming discharge. Dr. Liebsch explained that Chris was a good candidate for an advanced form of radiation therapy known as proton beam therapy.
Traditional radiation therapy delivers X-rays, a form of electromagnetic radiation, which enter into and exit out of the body. Along the way, they treat the tumor but damage healthy tissue nearby. In contrast, proton therapy delivers a high-energy, focused proton beam. The beam travels a limited and controlled distance into the tumor, but no further, leaving healthy tissue undamaged if administered properly.
At the time of Chris' treatment, Mass General patients received proton therapy at the Harvard Cyclotron Laboratory, located at Harvard University. Upon opening in 1949, the facility conducted research on nuclear physics. In the 1960s, Mass General physicians began collaborating with physicists and engineers at Harvard to apply the technology for clinical care.
Between 1961 and its closing in 2002, the Cyclotron provided proton therapy for more than 9,000 patients. Resection surgery followed by proton therapy is now the standard of care for treating chordoma.
"Previously, chordoma was considered a disease nonresponsive to radiotherapy and very difficult to cure with a very poor prognosis. Standard radiation therapy delivered in lower doses wasn't enough to control these tumors," Dr. MacDonald said. "Our predecessors at Mass General discovered you could safely go to higher doses of radiation using proton therapy, and that led to a curative treatment for chordoma."
Early on in his postsurgical treatment, Chris traveled to Mass General each morning for traditional radiation therapy and to the Cyclotron each evening for proton therapy. By the end of the six-week regimen, he was exclusively receiving proton therapy twice a day at the Cyclotron.
"It certainly was different going to the Cyclotron," he recalled. "For the traditional radiation, I went to a room at Mass General that felt like a medical facility. The Cyclotron was in an old physics building. It felt like walking into a machine. It was interesting but never bothered me."
Chris' regimen looked different than it would today. Now, treatment is typically delivered only with proton therapy once a day for eight weeks.
In 2001, four years after Chris' treatment, Mass General opened the Northeast Proton Therapy Center, later renamed the Francis H. Burr Proton Therapy Center. In 2020, the hospital opened the Gordon-Browne Proton Therapy Center. The two centers, which comprise New England's only proton therapy site, have treated more than 10,000 patients with proton therapy, including more than 1,000 cases of skull base chordoma.
According to Dr. MacDonald, Mass General Cancer Center has by far the most experience in treating chordoma with proton therapy. That has a major impact on patient outcomes.
"This is a very specialized treatment that, if delivered incorrectly, would be catastrophic to the patient," she said. "It's critical that everyone from the physicians, physicists, and dosimetrists who create the proton radiation plan to the radiation therapists who administer the treatment get hands-on training from colleagues who have many years of experience doing this. That way, you ensure the benefits of the treatment outweigh the harm."
Dr. MacDonald added that the quality of chordoma care at Mass General is enhanced by a bi-monthly multidisciplinary skull base tumor board that reviews cases from around the world. Furthermore, the Stephan L. Harris Center for Chordoma Care brings Mass General Cancer Center's multidisciplinary expertise to the evaluation, treatment, and support of patients with chordoma.
Chris, who described his life as "fantastic," is grateful for his wife, their two kids, and his health. He makes a point to stay active through mountain biking and other outdoor activities. For those who are diagnosed with chordoma, he encourages trying to maintain a positive outlook.
"Having that mentality of putting it behind you and not focusing on the negative scenarios that could happen is huge," he said. "Obviously, not everyone will be as lucky as I've been. But I think that being able to look forward and understand that life continues has been a huge part of my recovery."